- Target disease: VL
- Main partners (since project start): Accelera, Italy; Advinus Therapeutics Ltd, India; Aptuit, Italy; London School of Hygiene & Tropical Medicine, UK; TB Alliance, USA; Auckland University, New Zealand; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; Penn Pharmaceuticals Services, UK; Syngene, India; WuXi AppTech, China.
- Project start: September 2015
- Funding (since project start): Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW); Médecins Sans Frontières/Doctors without Borders.
Following the termination of the VL-2098 project in early 2015, two lead compounds from the nitroimidazooxazine back-up programme were progressed. One of these, DNDI-0690, showed good to excellent activity in vitro against both VL and CL causing strains of Leishmania and was nominated as a preclinical candidate in September 2015.
DNDI-0690 and other potential lead compounds for VL were profiled in vitro against CL-causing strains of Leishmania at the London School of Hygiene & Tropical Medicine and the Walter Reed Army Institute of Research.
In 2016, DNDi activities focused on pharmaceutical development activities (drug substance and drug product development and manufacture), launching of toxicity/safety pre-IND package with dose range finding studies, as well as refinement of ADME, efficacy and safety profile to ensure a smooth transition from the pre-clinical phase to Phase I clinical phase, which should happen over the course of 2017.
Last update: August 2017